explore -WSS

explore

author：Wikipedia 2025-09-29 13:30:58 - browse：573

Liver illustration — Hyacinth Empinado/STAT

SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.

GLP-1 treatments, such as Ozempic and Mounjaro, are a class of drugs that have grown widely popular for their efficacy not only in lowering blood sugar, but also cutting weight. Drugmakers have started to study them in liver disease, and while some trials have shown they may offer some benefits, they haven’t yet been shown to improve harmful liver scarring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Eli Lilly expects to double planned employment in Boston center

knowledge

WSS

Gene therapy’s promise and the high cost of hope

Brain injuries and the importance of a second opinion

Senate committee scrutinizes Medicare Advantage brokers

Live blog: Hearing on CRISPR

Medicare proceeds with plan to claw back hospital funds

The health care issue Democrats can’t solve: hospital reform

explore

explore

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Readout Newsletter: Today's biggest biotech updates

Heart attack and stroke risk calculators need revising

FDA warns J&J's Abiomed: We will regulate your software

How to save PrEP access — and even expand it

FDA gives detailed accounting of AI

In Memoriam: Notable people who died in 2023

Impact of Dobbs ruling felt at reproductive medicine meeting

Supreme Court strikes down use of affirmative action

FDA struggles to regulate food additives, sometimes for decades

focus

The explosion of genetic testing requires a new approach

Pharmacists can make shortage drugs, but at what cost?

Explaining an after

Sarepta Duchenne therapy fails to meet primary endpoint in trial

STAT Summit: GSK CEO on pharma giant's new direction

Senate committee scrutinizes Medicare Advantage brokers

hotspot

entertainment

knowledge

Wikipedia